CCL2 and metabolic dysfunction-associated steatotic liver disease: While an introduction of CCL-2 and FasL into clinical practice of NAFLD diagnostics may not be immediate, our study demonstrates that the pathway analysis technologies may hold their promise to make the process of in silico biomarker discovery more systematic and customizable.